AQP-007 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 85
    Alomone Labs anti aqp7
    Empagliflozin causes no significant changes to AQP3 and AQP1 but tends to increase <t>AQP7</t> level in diabetic rat kidneys. (A) Representative renal sections immunostained with anti-AQP3. (B) Quantitative analysis of results for AQP3 shows no significant change among groups. Magnification, ×200. (C) Representative immunoblot reacting with anti-NCC, anti-α-ENaC and anti- γ-ENaC. (D) Densitometric analysis shows that the expression of AQP3 protein significantly increased in all OLETF rats. Lixisenatide treatment further increased the expression of AQP3. ∗ P
    Anti Aqp7, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti aqp7/product/Alomone Labs
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti aqp7 - by Bioz Stars, 2022-12
    85/100 stars
      Buy from Supplier

    Image Search Results


    Empagliflozin causes no significant changes to AQP3 and AQP1 but tends to increase AQP7 level in diabetic rat kidneys. (A) Representative renal sections immunostained with anti-AQP3. (B) Quantitative analysis of results for AQP3 shows no significant change among groups. Magnification, ×200. (C) Representative immunoblot reacting with anti-NCC, anti-α-ENaC and anti- γ-ENaC. (D) Densitometric analysis shows that the expression of AQP3 protein significantly increased in all OLETF rats. Lixisenatide treatment further increased the expression of AQP3. ∗ P

    Journal: Frontiers in Physiology

    Article Title: Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys

    doi: 10.3389/fphys.2019.00271

    Figure Lengend Snippet: Empagliflozin causes no significant changes to AQP3 and AQP1 but tends to increase AQP7 level in diabetic rat kidneys. (A) Representative renal sections immunostained with anti-AQP3. (B) Quantitative analysis of results for AQP3 shows no significant change among groups. Magnification, ×200. (C) Representative immunoblot reacting with anti-NCC, anti-α-ENaC and anti- γ-ENaC. (D) Densitometric analysis shows that the expression of AQP3 protein significantly increased in all OLETF rats. Lixisenatide treatment further increased the expression of AQP3. ∗ P

    Article Snippet: Membranes were incubated with the following primary antibodies: AQP1 (Alomone Labs, Jerusalem, Israel), AQP2 (Alomone Labs), p261-AQP2 (Novus Biologicals, Littleton, CO, United States), AQP3 (Alomone Labs), AQP7 (Alomone Labs), cyclin-dependent kinase 1 (cdk1; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, United States), cdk5 (Santa Cruz Biotechnology, Inc.), Na+/H+ exchanger isoform 3 (NHE3; StressMarq Biosciences Inc., Victoria, BC, Canada), extracellular signal–regulated kinase (ERK; Cell Signaling Technology, Danvers, MA, United States), p-Erk (Cell Signaling Technology), p -glycogen synthase kinase 3α (pGSK3α; Santa Cruz Biotechnology, Inc.), Na+-Cl- cotransporter (NCC; StressMarq Biosciences), NKCC2 (StressMarq Biosciences), phosphatase 1β (PP1β; Santa Cruz Biotechnology, Inc.), PP2B (Santa Cruz Biotechnology, Inc.), vasopressin V2 receptor (V2R; Alomone Labs), α-epithelial Na+ channel (ENaC; StressMarq Biosciences); γ-ENaC (StressMarq Biosciences), p38 mitogen-activated protein kinase (p38; Cell Signaling Technology), p-p38 (Cell Signaling Technology) and β-actin (Sigma-Aldrich, St. Louis, MO, United States).

    Techniques: Expressing